<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Arterioscler Thromb Vasc Biol</journal-id><journal-id journal-id-type="iso-abbrev">Arterioscler Thromb Vasc Biol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Arteriosclerosis, thrombosis, and vascular biology</journal-title></journal-title-group><issn pub-type="ppub">1079-5642</issn><issn pub-type="epub">1524-4636</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11945546</article-id><article-id pub-id-type="pmcid-ver">PMC11945546.1</article-id><article-id pub-id-type="pmcaid">11945546</article-id><article-id pub-id-type="pmcaiid">11945546</article-id><article-id pub-id-type="manuscript-id">NIHMS2057155</article-id><article-id pub-id-type="pmid">39973747</article-id><article-id pub-id-type="doi">10.1161/ATVBAHA.124.321579</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2057155</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2057155</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development of zafirlukast analogues for improved anti-thrombotic activity through thiol isomerase inhibition</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Keovilay</surname><given-names initials="JA">Justine A.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Howard</surname><given-names initials="KC">Kaitlind C.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taylor</surname><given-names initials="KA">Kirk A.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khan</surname><given-names initials="S">Sabeeya</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wurl</surname><given-names initials="SE">Sienna E.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Szahaj</surname><given-names initials="MK">Melanie K.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sage</surname><given-names initials="T">Tanya</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chandrika</surname><given-names initials="NT">Nishad Thamban</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hou</surname><given-names initials="C">Caixia</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsodikov</surname><given-names initials="OV">Oleg V.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gibbins</surname><given-names initials="JM">Jonathan M.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garneau-Tsodikova</surname><given-names initials="S">Sylvie</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kennedy</surname><given-names initials="DR">Daniel R.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>College of Pharmacy and Health Sciences, Western New England University, Springfield, MA, 01119.</aff><aff id="A2"><label>2</label>Institute for Cardiovascular &amp; Metabolic Research, School of Biological Sciences, University of Reading, UK, RG6 6EX.</aff><aff id="A3"><label>3</label>Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone St., Lexington, KY, 40536.</aff><aff id="A4"><label>4</label>Department of Medicine, UMass Chan Medical School-Baystate, Springfield, MA, 01655.</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Authors contributions</p><p id="P2">J.A.K. and K.C.H. drafted the manuscript. K.C.H. and N.T.C. synthesized the zafirlukast analogues. J.A.K., S.K., and K.A.T. performed the platelet experiments. J.A.K., M.K.S., and S.E.W. performed the cell-free enzymatic assays. C.H. performed inhibitor binding assays. S.K. and K.A.T. performed intravital experiments and T.S. conducted tail bleeding assays. D.K and J.M.G. designed experiments. S.K., J.A.K., O.V.T., and S.G.-T. prepared the figures for the manuscript. D.R.K., J.M.G., S.G.-T., and O.V.T. supervised the project, edited the manuscript and supporting information, and provided funding for the work.</p></fn><corresp id="CR1"><bold>Corresponding Author:</bold> Daniel R. Kennedy, Department of Pharmaceutical &amp; Administrative Sciences, College of Pharmacy and Health Sciences, Western New England University, 1215 Wilbraham Road, Springfield, MA, 01119. <email>dkennedy@wne.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>2</month><year>2025</year></pub-date><volume>45</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">485352</issue-id><fpage>e136</fpage><lpage>e149</lpage><pub-history><event event-type="nihms-submitted"><date><day>25</day><month>02</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-28 00:25:17.870"><day>28</day><month>03</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2057155.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P3">Thiol isomerases play essential and non-redundant roles in platelet activation, aggregation, and thrombus formation. Thiol isomerase inhibitors have the potential to overcome the two major drawbacks of current antithrombotic therapies, as they target both arterial and venous thrombosis without enhancing bleeding risks. Recently, an FDA-approved drug, zafirlukast (ZAF), was shown to be a promising pan-thiol isomerase inhibitor. The objective of this study is to develop analogues of ZAF with optimized thiol isomerase inhibition and antithrombotic activity.</p></sec><sec id="S2"><title>Methods:</title><p id="P4">35 ZAF analogues were tested in an insulin turbidometric assay for thiol isomerase inhibition. Analogues were tested for platelet activation, aggregation, P-selectin expression, and laser-induced thrombosis in mice and compared with the parent compound.</p></sec><sec id="S3"><title>Results:</title><p id="P5">Of the 35 analogues, 12 retained activity, with one, compound <bold>21</bold> that demonstrated a greater potency than that of ZAF, 5 had a similar potency to that of ZAF, and 6 had a weaker potency. Analogues demonstrated inhibition of platelet aggregation and P-selectin expression as compared to ZAF, consistent with their potencies. ZAF and compound <bold>21</bold> were shown to be reversible inhibitors of thiol isomerases, and not cytotoxic to cultured, lung, liver, and kidney cells. Finally, in an <italic toggle="yes">in vivo</italic> assessment of thrombus formation, compound <bold>21</bold> was able to significantly inhibit thrombus formation without affecting bleeding times.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P6">A ZAF analogue, compound <bold>21</bold>, with properties superior to those of ZAF was synthesized, demonstrating improved inhibition of platelet activation, aggregation, and thrombus formation as compared to the parent ZAF. This approach could yield a promising clinical candidate for treatment and prophylaxis of arterial and venous thrombosis.</p></sec></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P7">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihms-2057155-f0001.jpg"/>
</p></abstract><kwd-group><kwd>Drug repurposing</kwd><kwd>Zafirlukast</kwd><kwd>PDI</kwd><kwd>Structure-activity relationship</kwd><kwd>Thiol isomerase</kwd><kwd>Thrombosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>